Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 18/20 | 1.00 |
| ▸ | PDE4A | P27815 | 12/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 12/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372989 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537071 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL3355989 | 0.99 | PDE4B (0.98) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977585 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3358462 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1194004 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977589 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537162 | 0.93 | PDE4B (0.86) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537193 | 0.91 | PDE4B (0.83) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL7109678 | 0.90 | PDE4B (0.84) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073354-A | Preparation method of apremilast intermediate | 江苏润安制药有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-10287248-B2 | Process for the preparation of apremilast | CIPLA LIMITED (IN) | 2019-05-14 | — | — | US | claimed |
| US-20180237390-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | CIPLA LIMITED (IN) | 2018-08-23 | — | — | US | claimed |
| EP-3271330-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | Cipla Limited (IN) | 2018-01-24 | — | — | EP | claimed |
| WO-2016146990-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | CIPLA LIMITED (IN) | 2016-09-22 | — | — | WO | claimed |
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-11987556-B2 | Dual-functional compounds and methods of use | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-05-21 | — | — | US | disclosed |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117203196-A | PDE4 degrading agents, pharmaceutical compositions and therapeutic applications | 拜欧斯瑞克斯公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4259621-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-113767104-B | Bifunctional compounds and methods of use thereof | 百放英库医药科技(北京)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-2263669-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2255801-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7678825-B2 | Pharmaceutically active isoindoline derivates | CELGENE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| EP-1228071-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1698334-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | MAN HON-WAH | 2004-07-29 | — | — | US | disclosed |
| US-6667316-B1 | Amido or imido functionality; tumor necrosis factor alpha, phosphodiesterases, matrix metalloproteases and angiogenesis inhibitors | CELGENE CORPORATION | 2003-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | PDE3A, PDE2A, PDE5A | PDE4B 10/4885PDE4C 8/4885PDE4A 6/4885 |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | PDE3A, PDE5A, PDE2A | PDE4B 14/4885PDE4C 10/4885PDE4A 6/4885 |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4C 6/4885PDE4A 1/4885 |
| US-20180237390-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | ACE, CMA1, APRT | PDE4B 174/4885PDE4C 556/4885PDE4A 127/4885 |
| US-11987556-B2 | Dual-functional compounds and methods of use | PDE1A, PDE3B, PDE1B | PDE4B 19/4885PDE4C 15/4885PDE4A 16/4885 |
| US-10287248-B2 | Process for the preparation of apremilast | ACE, CMA1, AGTR1 | PDE4B 149/4885PDE4C 494/4885PDE4A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.